Anika Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/28/2024
Anika Therapeutics Stock Forecast and Price Target
If the average 2024 price target of $32.00 recently set by two prominent experts for Anika Therapeutics is met, there would be a potential upside of approximately 25.15% from the last closing price in April, 2024. The high estimate is $37.00, and the low is $22.00. If interested in ANIK stock, you may also want to consider its competitors.
25.15% Upside
Anika Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Anika Therapeutics's Price has decreased from $14.07 to $0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach $27.50 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$335.61 | Buy/Sell | $353.16 | 9.20% |
| ZBH Stock Forecast | Zimmer Biomet Holdings | Hold |
15
|
$119.35 | Buy/Sell | $132.52 | 13.95% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.13 | Buy/Sell | $44.86 | 12.14% |
| SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£9.81 | Buy/Sell | £16.09 | 67.28% |
| ENOV Stock Forecast | Enovis | Buy |
15
|
$55.26 | Buy/Sell | $70.50 | 35.72% |
Anika Therapeutics Revenue Forecast for 2023 - 2025 - 2030
Anika Therapeutics's Revenue has seen growth In the last two years, going from $130.46M to $156.24M – a gain of 19.76% In the next year, analysts believe that Revenue will reach $179.43M – an increase of 14.84%. For the next seven years, the forecast is forRevenue to grow by 51.41%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VCEL Stock Forecast | Vericel | Buy |
8
|
$46.05 | Buy/Sell | $42.58 | 19.44% |
| AVNS Stock Forecast | Avanos Medical | Hold |
11
|
$18.10 | Buy/Sell | $23.50 | 29.83% |
| OFIX Stock Forecast | Orthofix Medical | Hold |
10
|
$12.99 | Buy/Sell | $18.00 | 15.47% |
.jpg)
Anika Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Anika Therapeutics has seen a decline in its EBITDA, from $14.82M to $-1.71M – a 111.54% decrease. According to the 2 analysts polled, in the next year, Anika Therapeutics's EBITDA will fall by 1170.18%, reaching $18.30M. By 2030, professionals believe that Anika Therapeutics's EBITDA will have decreased by 1921.66%, falling to $31.15M.
Anika Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Anika Therapeutics's EBIT has decreased by 1300.00%, from $1.35M to $-16.20M. For the next year, 2 analysts project Anika Therapeutics's EBIT to drop by 20.19%, reaching $-12.93M. By 2030, professionals believe that Anika Therapeutics's EBIT will decrease by 110.23%, reaching $1.66M – a concerning trend for the company.
Anika Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Anika Therapeutics's EPS has decreased from $0.71 to $0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach $-0.32 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
.jpg)